News | Stents Drug Eluting | May 31, 2018

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable Drug-Carrier DES in Acute Coronary Syndrome Patients

Optimax TiNO-coated stent displayed better safety outcomes at 18 months without compromising target lesion revascularization

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

May 31, 2018 – Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-nitride-oxide (TiNO)-coated Optimax stent was superior to the Synergy bioresorbable polymer coated metallic everolimus-eluting stent (EES) in acute coronary syndrome (ACS) patients. Results were presented by Pasi Karjalainen, M.D., Heart Center, Satakunta Central Hospital, Pori, Finland.

“At 18 months post-percutaneous coronary intervention (PCI), the TIDES-ACS results reveal that the Optimax nitride-oxide coated stent is superior in patients with acute coronary syndrome compared to one of the top drug-eluting stents used in current interventional cardiology,” stated Karjalainen.

Conducted in 12 international sites, this study randomised 1,491 ACS patients (2:1) to receive either TiNO-coated stents (n=989) or EES (n=502).

The co-primary endpoint (composite of cardiac death, re-infarction and major bleeding) occurred in 3.7 percent of patients receiving TiNO-coated stents, versus 7.8 percent of those receiving EES (superiority P=0.001).

For individual major adverse cardiac event (MACE) components at 18 months, both cardiac death (0.6 percent versus 2.6 percent, respectively; p=0.002) and non-fatal myocardial infarction (MI) (2.2 percent versus 5 percent, respectively; p=0.004) were observed less frequently with TiNO-coated stents. Ischemia-driven target lesion revascularization (TLR) occurred more frequently in the TiNO-coated stent arm, although this trend was not statistically significant (5.8 percent versus 4.4 percent, respectively; p=0.26 NS).

These results follow the previously reported 12-month primary endpoint results, where MACE occurred in 6.3 percent of patients receiving TiNO-coated stents, versus 7 percent of those receiving EES (p for non-inferiority <0.001).

“When considering the cumulative incidence of safety events, the Optimax stent displayed a 4.1 percent difference compared to Synergy, a significant advantage for patients treated with TiNO-coated stents,” said Karjalainen.  

In conclusion, for patients presenting with ACS, cobalt-chromium-based TiNO-coated stents were superior to platinum-chromium-based bioabsorbable polymer EES for the primary composite of safety outcome at 18-month follow-up without compromising the TLR rate (p=0.26 NS).   

“[The] TIDES-ACS trial is the first adequately powered head-to-head randomized comparison of contemporary bioactive stent technology with cutting-edge DES technology, in the setting of ACS. It provided sound evidence of superiority of the former, compared with the latter, for the composite of hard safety endpoints.” said Karjalainen, the principal investigator of this study.

“Based on this solid premise, we can advocate the use of [the] TiNO-coated BioActive Stent (BAS) as a worthwhile alternative to DES in ACS. It is our aspiration that stents based on this bioactive technology will be embraced by the upcoming Practice Guideline committees, as a viable and valid option for PCI in ACS patients." he added.

For more information: www.hexacath.com

Find links to other EuroPCR 2018 late-breaking trials.

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init